Opus Genetics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Opus Genetics, Inc. (IRD) had Deferred Tax Assets, Operating Loss Carryforwards of $32.25 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $32.25M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $20.34M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $12.78M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $13.09M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $32.25M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $20.34M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $12.78M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $13.09M 10-K · filed 2024-03-08 | |
| 2021-12-31 | $19.24M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $3.35M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $45.32M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $44.84M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $44.23M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $1.23M 10-K · filed 2021-03-11 | $43.84M 10-K · filed 2020-02-21 |
| 2019-09-30 | $43.27M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $42.68M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $42.30M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $41.18M 10-K · filed 2020-02-21 | |
| 2018-09-30 | $39.90M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $38.74M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $37.49M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $35.80M 10-K · filed 2019-03-07 | |
| 2017-09-30 | $48.17M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $46.65M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $45.14M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $43.53M 10-K · filed 2018-03-09 | |
| 2016-09-30 | $43.09M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $41.77M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $40.40M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $38.59M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $37.05M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $35.30M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $33.57M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $31.83M 10-K · filed 2016-03-14 | |
| 2014-09-30 | $30.44M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $29.17M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $27.96M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $26.92M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $26.09M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $25.39M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $24.68M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $24.09M 10-K · filed 2014-03-21 | |
| 2012-09-30 | $23.67M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $23.00M 10-Q · filed 2012-08-08 | |
| 2011-12-31 | $21.60M 10-K · filed 2013-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |